The Food and Drug Administration (FDA) said in a report on Friday that Pfizer-BioNTech’s COVID-19 vaccine meets the agency’s criteria for the immune response it generated in children aged 5 to 11; the agency also said that the vaccine would likely provide more benefits than risks in most scenarios. The FDA briefing document (pdf) was published ahead of a scheduled meeting of a panel of outside experts on Oct. 26. Members of the Vaccines and Related Biological Products Advisory Committee are to vote on that day on whether they would recommend the FDA to authorize the shots. In the document, the FDA acknowledged results from Pfizer released earlier in the day that said the two-dose vaccine was nearly 90.7 percent effective against the CCP (Chinese Communist Party) virus in a clinical trial of the children aged 5–11. Pfizer’s clinical trial was not primarily designed to measure efficacy against the virus. The trial compared the amount …
RSS Feed | The Epoch Times